Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
7(88%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
38%
Ph not_applicable
2
25%
Ph phase_2
2
25%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
3(42.9%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

8

all time

Status Distribution
Active(7)
Completed(1)

Detailed Status

Recruiting4
Active, not recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
7
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (28.6%)
Phase 33 (42.9%)
N/A2 (28.6%)

Trials by Status

active_not_recruiting338%
recruiting450%
completed113%

Recent Activity

7 active trials
Showing 5 of 8
active_not_recruitingphase_3

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257
active_not_recruitingphase_2

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

NCT00756639
active_not_recruitingphase_3

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204
recruitingphase_3

Omitting CTV for Primary Tumor in LS-SCLC

NCT07008716
recruiting

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

NCT06869239
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05353257Phase 3

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active Not Recruiting
NCT00756639Phase 2

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Active Not Recruiting
NCT04624204Phase 3

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Active Not Recruiting
NCT07008716Phase 3

Omitting CTV for Primary Tumor in LS-SCLC

Recruiting
NCT06869239

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

Recruiting
NCT05443646Phase 2

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Recruiting
NCT02397733Not Applicable

Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)

Completed
NCT03514849Not Applicable

Clinical Study of Combined Radical Operation With Postoperative Adjuvant Chemotherapy and Prophylactic Cranial Irradiation in pT1-2N0M0 Stage of Small Cell Lung Cancer

Recruiting

All 8 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
8